We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

182 hedge funds and large institutions have $1.83B invested in Aerie Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 78 increasing their positions, 47 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $33.7M | Put options by funds: $18M

66% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 47

58% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 19

6% more funds holding

Funds holding: 172 → 182 (+10)

1% more capital invested

Capital invested by funds: $1.81B → $1.83B (+$16.8M)

22% less funds holding in top 10

Funds holding in top 10: 9 → 7 (-2)

Holders
182
Holders Change
+10
Holders Change %
+5.81%
% of All Funds
4.54%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.17%
New
30
Increased
78
Reduced
47
Closed
19
Calls
$33.7M
Puts
$18M
Net Calls
+$15.8M
Net Calls Change
+$17.9M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$84.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$46M
3
PHS
PFM Health Sciences
California
+$36.3M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$15.2M
5
WRF
Waddell & Reed Financial
Kansas
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$21.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$20.5M
3
DM
Deerfield Management
New York
-$17.9M
4
Deutsche Bank
Deutsche Bank
Germany
-$17.6M
5
BC
Broadfin Capital
New York
-$13.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
FRM
126
Fox Run Management
Connecticut
$355K -$256K -4,700 -39%
AP
127
AHL Partners
United Kingdom
$337K +$378K +6,932 New
GC
128
Guggenheim Capital
Illinois
$324K +$364K +6,672 New
GCP
129
GSA Capital Partners
United Kingdom
$313K +$83.9K +1,538 +31%
BAMCO Inc
130
BAMCO Inc
New York
$299K +$35.2K +645 +12%
G
131
Gainplan
Michigan
$292K +$87.3K +1,600 +36%
FMT
132
First Mercantile Trust
Tennessee
$291K +$25.9K +474 +9%
Barclays
133
Barclays
United Kingdom
$277K +$124K +2,279 +66%
Federated Hermes
134
Federated Hermes
Pennsylvania
$276K -$37.2K -682 -11%
Los Angeles Capital Management
135
Los Angeles Capital Management
California
$276K +$309K +5,670 New
Principal Financial Group
136
Principal Financial Group
Iowa
$274K -$135K -2,481 -31%
PP
137
Paloma Partners
Connecticut
$271K +$304K +5,573 New
UCFA
138
United Capital Financial Advisors
Texas
$268K +$709 +13 +0.2%
CG
139
Colony Group
Massachusetts
$261K – – –
AG
140
Aperio Group
California
$253K +$16.5K +303 +6%
FO
141
FT Options
Illinois
$246K +$37.4K +685 +16%
LCM
142
Laurion Capital Management
New York
$233K +$262K +4,800 New
SM
143
Sabby Management
Florida
$230K +$258K +4,726 New
Jane Street
144
Jane Street
New York
$230K +$258K +4,729 New
TRCT
145
Tower Research Capital (TRC)
New York
$226K +$241K +4,414 +1,862%
PCM
146
Palisade Capital Management
New Jersey
$207K +$11.3K +207 +5%
Creative Planning
147
Creative Planning
Kansas
$204K +$32.7K +600 +17%
Canada Life
148
Canada Life
Manitoba, Canada
$204K +$89.4K +1,639 +65%
LTFS
149
Ladenburg Thalmann Financial Services
Florida
$204K +$229K +4,200 New
AB
150
Amalgamated Bank
New York
$203K +$16.3K +299 +8%
4 5
6
7 8

AERI Hedge Fund Activity: Q3 2017 in Review

182 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2017, worth a combined $1.83B — up 0.93% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AERI positions and 19 closed out — a net gain of 11 holders — while 78 added to existing stakes and 47 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $84.7M. The largest seller was OrbiMed, cutting an estimated $21.5M.

  • 182 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2017, up from 172 in Q2 2017.
  • Funds reported $1.83B of Aerie Pharmaceuticals stock for Q3 2017, up 0.93% quarter-over-quarter.
  • 30 funds opened new Aerie Pharmaceuticals positions in Q3 2017 and 19 closed out, a net change of +11 holders.
  • The largest Aerie Pharmaceuticals buyer in Q3 2017 was Wellington Management Group, an estimated $84.7M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2017 was OrbiMed, an estimated $21.5M sold.

Based on aggregated 13F filings for Q3 2017.